Fig. 3: DAXX inhibits SARS-CoV-2 at an early post-entry step.
From: Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen
a DAXX has no effect on Spike-mediated entry. A549-ACE2 WT or DAXX KO were infected with the GFP reporter viruses VSV* or VSV*∆G-S. Cell monolayers were harvested at 16 h p.i. and analyzed by flow cytometry. The mean of 3 independent experiments ± SD is shown. Statistics: 2-way ANOVA using Sidak’s test. P values are indicated on the graph. b, c DAXX inhibits viral RNA synthesis. A549-ACE2 WT or DAXX KO were infected at an MOI of 1. Cell monolayers were harvested at the indicated time points, and total RNA was extracted. The levels of viral RNA (c: 5ʹ UTR; d: RdRp) were determined by qRT-PCR and normalized against GAPDH levels. The mean ± SD of 3 independent experiments, with infections carried out in three biological replicates, is represented. Statistics: Dunnett’s test on a linear model (two-sided). Significant p values (below 0.05) are indicated on the graph. d DAXX inhibits viral protein synthesis. A549-ACE2 WT or DAXX KO were infected at an MOI of 2. Cell monolayers were harvested at the indicated time points and Spike levels were quantified by flow cytometry. The mean of 3 independent experiments ± SD is represented. Statistics: 2-way ANOVA using Sidak’s test. P values are indicated on the graph. Source data are provided as a Source Data file.
